Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Advanced Chemotherapy Technologies
AddedFeb 15, 2024
UpdatedJun 18, 2026
Advanced Chemotherapy Technologies

Advanced Chemotherapy Technologies

Series A

Advanced Chemotherapy Technologies: Innovating cancer treatment with groundbreaking medical tech solutions.

HQ
Raleigh, NC, US
Founded
2014
Overview
Compare
Fundraising
Employees

Advanced Chemotherapy Technologies is a medical technology company dedicated to developing innovative chemotherapy delivery solutions for cancers that are challenging to treat with systemic therapy alone. Their mission is to enhance the effectiveness of cancer treatments and improve patient outcomes through cutting-edge medical technology.

The company has achieved significant milestones in advancing localized chemotherapy delivery methods, potentially reducing side effects and increasing treatment efficacy. Their pioneering work has positioned them as a leader in the field of targeted cancer therapies, making a substantial impact on the lives of patients.

Advanced Chemotherapy Technologies - Similar Companies

Advanced Cancer Therapeutics logo

Advanced Cancer Therapeutics

Delcath Systems logo

Delcath Systems

delcath.com

Chimeros logo

Chimeros

Civatech Oncology logo

Civatech Oncology

PanTher Therapeutics logo

PanTher Therapeutics

panthertx.com

Advanced Medical Device Technologies logo

Advanced Medical Device Technologies

advancedmdt.com

Oncology Honduras logo

Oncology Honduras

Palm Therapeutics logo

Palm Therapeutics

LifeBridge Innovations logo

LifeBridge Innovations

PNP Therapeutics logo

PNP Therapeutics

Otricath logo

Otricath

Cure Forward logo

Cure Forward

OncoPrecision logo

OncoPrecision

oncoprecision.bio

Oncologix Tech logo

Oncologix Tech

Ascenta Therapeutics logo

Ascenta Therapeutics

Advanced Chemotherapy Technologies - Quick Facts

Who are Advanced Chemotherapy Technologies' competitors?

Companies similar to Advanced Chemotherapy Technologies include Advanced Cancer Therapeutics, Delcath Systems, Chimeros and Civatech Oncology.

When was Advanced Chemotherapy Technologies founded?

Advanced Chemotherapy Technologies was founded in 2014.

Where is Advanced Chemotherapy Technologies' headquarters located?

Advanced Chemotherapy Technologies' headquarters is located in Raleigh, NC, US.

When was Advanced Chemotherapy Technologies' last funding round?

Advanced Chemotherapy Technologies' most recent funding round was for $4M (USD) in August 2021.

How much has Advanced Chemotherapy Technologies raised to-date?

As of Aug 12, 2021, Advanced Chemotherapy Technologies has raised a total of $14.9M (USD).

How many employees does Advanced Chemotherapy Technologies have?

Advanced Chemotherapy Technologies has 13 employees as of Feb 5, 2024.

Advanced Chemotherapy Technologies - Classification

Industry
  • Hardware
Ownership
  • Private
Technology
  • Biotech
Geographic Exposure
  • Americas
Revenue
  • Transactional
Main Product
  • Medical Devices
Tags
  • Healthtech
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 325410Pharmaceutical and Medicine Manufacturing
SIC
  • 5000Wholesale Trade-durable Goods
  • 5040Professional And Commercial Equipment And Supplies
  • 5047Medical, Dental, And Hospital Equipment And Supplies
Show 7 more industry codes
NAICS
  • 330000Manufacturing
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 3900Miscellaneous Manufacturing Industries
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified